key: cord-0865800-uaa2kljz
authors: Massie, Allan B.; Werbel, William A.; Avery, Robin K.; Po‐Yu Chiang, Teresa; Snyder, Jon J.; Segev, Dorry L.
title: Quantifying excess deaths among solid organ transplant recipients in the COVID‐19 era
date: 2022-04-02
journal: Am J Transplant
DOI: 10.1111/ajt.17036
sha: 5eaa523cef3b7fb47fd1eba06eb70955c8d305ca
doc_id: 865800
cord_uid: uaa2kljz

Estimating the total coronavirus disease 2019 (COVID‐19) mortality burden of solid organ transplant recipients (SOTRs), both directly through COVID‐19 infection and indirectly through other impacts on the healthcare system and society, is critical for understanding the disease's impact on the SOTR population. Using SRTR data, we modeled expected mortality risk per month pre‐COVID (January 2015–February 2020) for kidney/liver/heart/lung SOTRs, and compared monthly COVID‐era deaths (March 2020–March 2021) to expected rates, overall and among subgroups. Deaths above expected rates were designated "excess deaths." Between March 2020 and March 2021, there were 3739/827/265/252 excess deaths among kidney/liver/heart/lung SOTRs, respectively, representing a 41.2%/27.4%/18.5%/15.0% increase above expected deaths. 93.0% of excess deaths occurred in patients age≥50. The observed:expected ratio was highest among Hispanic SOTRs (1.82) and lowest among White SOTRs (1.20); 56.0% of excess deaths occurred among Black or Hispanic SOTRs. 64.7% of excess deaths occurred among patients who had survived ≥5 years post‐transplant. Excess deaths peaked in January 2021; geographic distribution of excess deaths broadly mirrored COVID‐19 incidence. COVID‐19 likely caused over 5000 excess deaths among SOTRs in the US in a 13‐month period, representing 1 in 75 SOTRs and a substantial proportion of all deaths among SOTRs during this time. SOTRs will remain at elevated mortality risk until the COVID‐19 pandemic can be controlled.

procedures, avoidance of hospitals or emergency departments, and even "deaths of despair"-suicides, drug overdoses, and alcoholrelated liver disease. [3] [4] [5] High COVID-19 case-fatality rates have been reported among solid organ transplant recipients (SOTRs), 6-10 but the total mortality burden among transplant recipients is unknown. Estimating total mortality due to the COVID-19 epidemic among SOTRs is critical for understanding the impact of the pandemic on the transplant population, and has implications for the broader US population living with chronic disease.

To estimate deaths attributable to the COVID-19 pandemic, we conducted a retrospective study using national registry data from the United States. contractors. This dataset has previously been described elsewhere. 11 This study was classified as "exempt-not human subjects research" by the Johns Hopkins School of Medicine Institutional Review Board.

The study population consisted of kidney, liver, heart, and lung transplant recipients who were residents of the United States (the 50 US states, the District of Columbia, or Puerto Rico); who received a transplant between July 1, 2004 and March 31, 2020; and who were alive on January 1, 2015. SOTRs who received a transplant before July 1, 2004 were excluded because the state of residence was not available for such recipients.

To model the expected death rate among SOTRs we used a discretetime proportional hazards framework. Specifically, separately for kidney, liver, heart, and lung recipients, we created a dataset of pre-COVID person-months January 2015-February 2020. Using this dataset, we modeled the probability of death in each person-month using multilevel logistic regression with a random intercept for the state of residence at time of transplant and adjusting for age (categorized as 

Overall and for various subgroups, we compared observed deaths to 

Observed deaths exceeded expected deaths each month during the study period ( Figure 1A ). Excess deaths reached an initial peak in April 2020, then declined in May and June 2020. They reached a smaller secondary peak in July 2020, declined until September 2020, and then increased dramatically, reaching a maximum in January 2021. This temporal pattern corresponded to temporal patterns in COVID-associated mortality in the United States. The ratio of observed to expected deaths followed similar temporal patterns in each organ group, although there was less temporal variation for liver recipients than for other organ groups ( Figure 1B ).

The ratio of observed to expected deaths showed a strong age gradient ( Table 1) 

In this national study of mortality among SOTRs during the COVID-19 era, we estimated that there were 5083 excess deaths in the United States in the first 13 months of the pandemic, representing 1 in 75 SOTRs and a substantial proportion of all deaths among SOTRs during the study period. Excess deaths occurred in every month of the COVID era, peaking in January 2021. Although a statistically significant number of excess deaths were observed across categories of organ type, age (except for children and adults under the age of 30), sex, race, and insurance type, the apparent increase in mortality was higher for kidney recipients than for recipients of other organs; higher for older adults; and higher for men than for women. There was substantial variation by race/ethnicity, with the greatest increase seen among Hispanic SOTRs (82% above expected) and the smallest increase among White SOTRs (20% above expected). Spatio-temporal patterns of excess deaths match patterns of COVID-19 incidence in the United States, suggesting that the mortality increase is likely in fact due to the COVID-19 pandemic and not some other cause. Vaccination is a key factor in reducing death from COVID-19, but benefits may be attenuated in some SOT recipients. 15 Antibody responses and vaccine effectiveness versus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are dramatically lower after 2 mRNA vaccines and serious disease is more common. 16 Additional doses and booster vaccines ameliorate antibody and cellular responses in many SOT recipients, [17] [18] [19] yet some remain seronegative and likely at high risk of morbidity, particularly in light of the highly-resistant omicron variant. 20 It is probable that COVID-19 will be responsible for ongoing excess deaths in this population unless vaccine responses are improved and therapeutics including passive immunoprophylaxis and antiviral therapies are optimized.

Our study must be understood in the context of its limitations.

First, we cannot demonstrate that these excess deaths occurred be- 

Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity -United States

Excess deaths from COVID-19 and other causes

Every body counts: measuring mortality from the COVID-19 pandemic

Addiction as a coping response: hyperkatifeia, deaths of despair, and COVID-19

Suicide risk and prevention during the COVID-19 pandemic

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

COVID-19 in solid organ transplant: A multi-center cohort study

Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic

Big data in organ transplantation: registries and administrative claims

Effective communication of standard errors and confidence intervals

Excess death estimates in patients with end-stage renal disease -United States

IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)

Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients

A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients

Anti-SARS-CoV-2 spike protein and neutralizing antibodies at one and 3 months after 3 doses of SARS-CoV-2 vaccine in a large cohort of solid-organ-transplant patients

Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: A case series

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. medRxiv

Our findings demonstrate the profound impact of COVID-19 on the SOTR population in the first thirteen months in the United States. The advent of vaccines has led to substantially decreased incidence of COVID-19, and novel treatments may reduce the future mortality risk for COVID patients. Nevertheless, COVID-19 management and mitigation will continue to be an essential component of the medical treatment of SOTRs for some time to come.